Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat

Experimental and Molecular Pathology

Volumn 98, Issue 2, 2015, Pages 230-239

  Khan, Sabbir ^a   Jena, Gopabandhu ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetic nephropathy; HDAC inhibitor; Histone acetylation; Myofibroblast; Renal fibrosis; Sodium valproate; Transforming growth factor beta 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; FIBRONECTIN; GELATINASE A; HISTONE DEACETYLASE; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE H3; INTERCELLULAR ADHESION MOLECULE 1; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; VALPROIC ACID; CYTOKINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME INHIBITION; HISTONE ACETYLATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY INJURY; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION; WESTERN BLOTTING; ACETYLATION; ACUTE KIDNEY INJURY; ANIMAL; BIOSYNTHESIS; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; INJURIES; KIDNEY; MALE; METABOLISM; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

RATTUS;

ACETYLATION; ACUTE KIDNEY INJURY; ANIMALS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MATRIX METALLOPROTEINASE 2; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STREPTOZOCIN; VALPROIC ACID;

EID: 84924798483     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.01.003     Document Type: Article

References (51)

1. Aher J., et al. Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation. Hum. Exp. Toxicol. 2015, 34:44-55.
2. Ahmad T., et al. Pretreatment with valproic acid, a histone deacetylase inhibitor, enhances the sensitivity of the peripheral blood micronucleus assay in rodents. Mutat. Res. 2013, 751:19-26.
3. Ahmed S., et al. Largazole, a class I histone deacetylase inhibitor, enhances TNF-alpha-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts. Toxicol. Appl. Pharmacol. 2013, 270:87-96.
4. Ban C.R., Twigg S.M. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manag. 2008, 4:575-596.
5. Broekema M., et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J. Am. Soc. Nephrol. 2007, 18:165-175.
6. Carew J.S., et al. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269:7-17.
7. Castro N.E., et al. Transforming growth factor beta1 (TGF-beta1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. J. Biol. Chem. 2014, 289:29001-29013.
8. Chateauvieux S., et al. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010, 2010:1-18.
9. Chen Q., et al. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J. Immunotoxicol. 2011, 8:210-218.
10. Cook H.T. The origin of renal fibroblasts and progression of kidney disease. Am. J. Pathol. 2010, 176:22-24.
11. Fragiadaki M., Mason R.M. Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int. J. Exp. Pathol. 2011, 92:143-150.
12. Gilbert R.E., et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int. 2011, 79:1312-1321.
13. Glenisson W., et al. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim. Biophys. Acta 2007, 1773:1572-1582.
14. Gottlicher M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
15. Hannan J.L., et al. Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats. J. Sex. Med. 2014, 11:1442-1451.
16. Hellebrekers D.M., et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006, 66:10770-10777.
17. Hemmatazad H., et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum. 2009, 60:1519-1529.
18. Hinz B., et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816.
19. Hinz B., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 2012, 180:1340-1355.
20. Huber L.C., et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 2007, 56:2755-2764.
21. Kato M., Natarajan R. Diabetic nephropathy - emerging epigenetic mechanisms. Nat. Rev. Nephrol. 2014, 10:517-530.
22. Khan S., Jena G.B. Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre- and post-treatment schedule. Toxicol. Int. 2013, 70:68-76.
23. Khan S., Jena G. Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-beta1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem. Toxicol. 2014, 73:127-139.
24. Khan S., Jena G.B. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat. Chem. Biol. Interact. 2014, 213:1-12.
25. Khan S., Jena G. Sodium valproate, a histone deacetylase inhibitor ameliorates cyclophosphamide-induced genotoxicity and cytotoxicity in the colon of mice. J. Basic Clin. Physiol. Pharmacol. 2015, 1-11. (in press). 10.1515/jbcpp-2013-0134.
26. Khan S., et al. Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice. Reprod. Toxicol. 2011, 32:385-394.
27. Khan S., et al. Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-κB/iNOS signaling in diabetic rat. Biochimie 2015, (in press). 10.2016/j.biochi.2014.12.015.
28. Kliem V., et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996, 49:666-678.
29. Komorowsky C., et al. Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors. J. Cell. Mol. Med. 2009, 13:2353-2364.
30. Lee H.B., et al. Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int. Suppl. 2007, S61-6.
31. Li J., et al. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am. J. Pathol. 2006, 169:1527-1540.
32. Liu N., et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE 2013, 8:e54001.
33. Mannaerts I., et al. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 2010, 51:603-614.
34. Moore P.S., et al. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta 2004, 1693:167-176.
35. Noh H., et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am. J. Physiol. Renal Physiol. 2009, 297:F729-F739.
36. Reddy M.A., et al. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 2014, http://link.springer.com/article/10.1007/s00125-014-3462-y (in press online on Dec 7, 2014).
37. Riser B.L., et al. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J. Cell Commun. Signal. 2010, 4:39-50.
38. Sanders Y.Y., et al. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur. Respir. J. 2014, 43:1448-1458.
39. Shang Y., et al. Valproic acid attenuates the multiple-organ dysfunction in a rat model of septic shock. Chin. Med. J. (Engl.) 2010, 123:2682-2687.
40. Shen W., et al. Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. J. Cell. Physiol. 2008, 214:405-412.
41. Tervaert T.W., et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:556-563.
42. Van Beneden K., et al. Valproic acid attenuates proteinuria and kidney injury. J. Am. Soc. Nephrol. 2011, 22:1863-1875.
43. Van Beneden K., et al. HDAC inhibitors in experimental liver and kidney fibrosis. Fibrogenesis Tissue Repair 2013, 6:1.
44. Villeneuve L.M., Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal Physiol. 2010, 299:F14-F25.
45. Wang X., et al. Histone deacetylases and their inhibitors: molecular mechanisms and therapeutic implications in diabetes mellitus. Acta Pharma. Sin. B 2012, 2:387-395.
46. Wang X., et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney Int. 2014, 86:712-725.
47. Watanabe T., et al. Sodium valproate blocks the transforming growth factor (TGF)-beta1 autocrine loop and attenuates the TGF-beta1-induced collagen synthesis in a human hepatic stellate cell line. Int. J. Mol. Med. 2011, 28:919-925.
48. Yadav L., et al. Influence of 3-aminobenzamide, an inhibitor of poly(ADP-ribose)polymerase, in the evaluation of the genotoxicity of doxorubicin, cyclophosphamide and zidovudine in female mice. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2014, 770:6-15.
49. Yoshikawa M., et al. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J. Am. Soc. Nephrol. 2007, 18:58-65.
50. Yuan H., et al. Involvement of p300/CBP and epigenetic histone acetylation in TGF-beta1-mediated gene transcription in mesangial cells. Am. J. Physiol. Renal Physiol. 2013, 304:F601-F613.
51. Zhang Z., et al. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell. Mol. Life Sci. 2008, 65:4055-4065.